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2214-031X/Copyright ª 2014, The Aut
license (http://creativecommons.org/Summary Osteoporotic vertebral compression fractures (OVCFs) have gradually evolved into
a serious health care problem globally. In order to reduce the morbidity of OVCF patients and
improve their life quality, two minimally invasive surgery procedures, vertebroplasty (VP) and
balloon kyphoplasty (BKP), have been developed. Both VP and BKP require the injection of
bone cement into the vertebrae of patients to stabilize fractured vertebra. As such, bone
cement as the filling material plays an essential role in the effectiveness of these treatments.
In this review article, we summarize the bone cements that are currently available in the mar-
ket and those still under development. Two major categories of bone cements, nondegradable
acrylic bone cements (ABCs) and degradable calcium phosphate cements (CPCs), are intro-
duced in detail. We also provide our perspectives on the future development of bone cements
for VP and BKP.
Copyrightª 2014, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Ageing has become a global issue as a result of improved
living conditions and health care [1]. Due to inadequate
calcium and vitamin D intake, as well as reduced dailyBuilding 1, Soochow University (S
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licenses/by-nc-nd/4.0/).activities, there is a high incidence of osteoporosis in the
elderly. As a result, osteoporosis with subsequent vertebral
compression fractures (VCFs) has evolved into a common
social and economic burden globally. The annual incidence
of osteoporotic fractures exceeds 1.5 million in the US, ofouth Campus), 708 Renmin Road, Suzhou, Jiangsu 215007, China.
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2 Z. He et al.which more than 50% are VCFs, and this is twice the inci-
dence of hip fractures [2]. About 20% of individuals over 50
years old and 45% of women over 50 experience OVCFs. If
left untreated, OVCFs may lead to dramatic physical,
functional, and psychological consequences that impair the
quality of life of the patient [3]. VCF patients usually suffer
from severe back pain. Moreover, restrictive lung diseases
may develop when there are multiple thoracic fractures
[4]. In the worst cases, female VCF patients have a 23%
higher mortality rate compared to those without VCFs [5].
Until recently, conservative treatments have been the only
options [6].
In order to reduce the morbidity of patients with acute
OVCFs and improve their life quality, vertebroplasty (VP), a
minimally invasive surgery (MIS), was developed in the 1980s
by Galibert et al [7] (Fig. 1A,B). By using a needle to deliver
bone cement to fractured vertebra through the pedicle of
the vertebral arch, the VP technique successfully relieved
the pain of 75e85%of patients [8]. Compared to conservative
treatments, VP is safe, the pain relief after surgery is im-
mediate, and the effect can last for at least 1 year [6].
However, VP does not restore the height of the compressed
vertebral body (VB), which may reoccur in the later stage of
treatment such that the patients still suffer from kyphosis
and chronic low back pain. A variation of VP, kyphoplasty
(KP), attempts to restore the height and angle of kyphosis of
a fractured VB and to stabilize it using injected bone cement.Figure 1 (A) A schematic illustration of VP and BKP procedures.
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permission.BKP, developed in the 1990s by Dr Mark Reiley, is the most
commonly used KP technique. BKP involves the use of a
balloon to create a cavity within the cancellous bone, fol-
lowed with bone cement delivery to the cavity to reinforce
the VB (Fig. 1A,C). Using this technique, BKPnot only relieves
the back pain of the patient, but also corrects deformities
such as kyphosis. BKP also provides controlled cement filling
to make the cement more uniformly distributed within the
VB. While the extent of pain relief is similar, BKP results in
markedly fewer complications and has a lower risk of mor-
tality than VP [9,10]. However, the survival rates for VCF
patients following VP or BKP were all markedly higher than
nonoperated patients [10].
Apparently, the filling material, i.e., the bone cement,
plays a critical role in the effectiveness of VP or BKP
treatments. Bone cements for VP or BKP are self-curing
compounds that are applied in a flowable state and
become fully cured in the body to provide adequate sup-
port to the fractured VB. They must have considerable
mechanical strength and toughness in order to achieve
long-term sustainability. They should have adequate vis-
cosity and be injectable for facilitating VP or BKP sur-
geries. In addition, they should have appropriate working
and setting times to match the general progress of sur-
geries. They should also be radiopaque and present clear
contrast under fluoroscopy. These fundamental re-
quirements make VP and BKP bone cements a special(B) VP for a patient with severe vertebral compression: (aec)
howing severe H-shaped VCF at the T9 VB; (d) postoperational
patient with L1 vertebral compression: (aeb) X-ray radiograph
oroscopy image showing the filling of bone cement in a cavity
y images showing complete filling of bone cement and resto-
Z magnetic resonance; VBZ vertebral body; VCFZ vertebral
m “Unilateral versus bilateral vertebroplasty for severe osteo-
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Bone cements for VP and BKP 3category, which largely differs from the cements for other
purposes such as total hip arthroplasty (THA) or total knee
arthroplasty (TKA).
To date, the most popular bone cement is poly(methyl
methacrylate) (PMMA)-based acrylic bone cement (ABC).
However, several drawbacks of PMMA, including non-
biodegradability, monomer toxicity, heat generation during
exothermic polymerization, and leakage of monomer, limit
its applications. To overcome these disadvantages, biode-
gradable calcium phosphate cements (CPCs) and other
types of cements that generate no or little heat upon curing
have been developed and their applications in VP and BKP
have been recently explored. In this article, we summarize
the bone cements that are currently available in the market
and have been clinically used. We also provide our per-
spectives on the future development of bone cements for
VP and BKP.
ABCs
In 1958, Dr John Charnley [11] first started to use self-
curing PMMA cement in total hip replacement (THR) and
succeeded in anchoring femoral head prostheses in the
femur. Since this major breakthrough, use of PMMA-based
bone cements has prevailed in various orthopaedic appli-
cations. In 1987, Galibert et al [7] first used PMMA bone
cement to treat cervical vertebral haemangioma in pa-
tients. Since then, this technique has been successfully
applied to many spine disorders including OVCFs, vertebral
metastasis of malignant tumours, multiple myeloma, and
even traumatic VCFs. In 2004, the Food and Drug Adminis-
tration (FDA) formally approved PMMA bone cements for
treating vertebral fractures resulting from osteoporosis and
tumours. Advantages such as bio-inertness, ease of
handling, considerable mechanical strength, and cost-
effectiveness make PMMA an ideal choice for bone
cement. To date, ABCs represent the vast majority of bone
cements for VP and BKP.
Compositions of ABCs
The main components of ABCs are acrylic compounds that
are capable of self-curing. All of them are composed of
solid and liquid phases. When the solid and liquid phases of
an ABC are mixed, curing occurs rapidly at room or body
temperatures. The compositions of ABCs only vary slightly.
A large number of cement brands have been developed and
are commercially available (Table 1).
The solid phase of an ABC mainly comprises PMMA pre-
polymer and/or copolymers of acrylic acid (AA), ethyl
acrylate (EA), methyl acrylate (MA), MMA, and styrene. The
average molecular weight of the prepolymers ranges from
44,000 to 1,980,000, and the bead size ranges from 30 mm
to 150 mm. The prepolymer powder accounts for approxi-
mately 80 wt% of bone cement. The solid phase also con-
tains benzoyl peroxide (BPO) as the initiator, at a
concentration of 0.75e2.5 wt%. In addition, radiopacifiers,
such as barium sulfate, zirconium dioxide, tantalum, and
tungsten powders, are included in the powder to make the
cement radiographically visible. Their concentration is
generally 10e30 wt% of powder, and their particle size isaround 5 mm [12,13]. In order to prevent infection, some
commercial products also supplement antibiotics, including
gentamicin, keflin, erythromycin, and colistin, to the
powder. Occasionally, dyes or pigments such as chlorophyll
may also be supplemented to provide additional features to
cements.
The main composition of the liquid phase is MMA
monomer, usually at a concentration of 95 wt%. In order to
initiate polymerization, an activator N-N-dimethyl-p-tolui-
dine (DMPT) is usually supplied (0.89e2.7 wt%). In addition,
the liquid phase contains an inhibitor, usually hydroquinone
(HQ), which functions to inhibit premature polymerization
during storage [12,13].Current development of ABCs
Although the ABC industry is mature and a broad range of
products have appeared in the market, some drawbacks of
ABCs cannot be ignored, including nondegradability and
significant mechanical mismatch with the VB. As such,
many efforts have been made to improve the products in
terms of mechanical characteristics, porosity, biodegrad-
ability, and to provide additional merits such as osteo-
conductivity and drug delivery capability [14e16]. Such
improvements are mainly achieved by fabricating compos-
ite materials using ABCs and filling materials of desired
properties.
Cortoss Bone Augmentation Material represents a typical
composite ABC. It is a polymereinorganics composite con-
sisting of crosslinking resins and reinforcing glass ceramic
particles. It consists of a terpolymer resin containing
Bisphenol-A-glycidyl dimethacrylate (Bis-GMA), Bisphenol-
A-ethoxy dimethacrylate (Bis-EMA), and triethyleneglycol
dimethacrylate (TEGDMA). It is supplemented with bioac-
tive combeite glasseceramic particles for stimulating bone
apposition at the interface, barium boroaluminosilicate
glass for providing radiopacity and strength, and silica
particles for achieving adequate viscosity [17]. It functions
to strengthen weakened bone and achieves a compressive
strength equal to approximately 75% of human cortical
bone (210 megapascals, MPa) within 15 minutes of appli-
cation [18].
The porosity of ABC significantly affects its mechanical
and biological performance. Ideally, the cured cement as
an implant material within the VB should contain pores of
varying size and distribution to mimic the trabecular-like
structure of the VB. However, such a porous structure
inevitably weakens the mechanical properties of the
cement. Therefore, it is desired to have a composite
cement in which biodegradable fillers are embedded
throughout the cement to provide enough initial mechani-
cal strength. When they degrade, new bone ingrowth hap-
pens so that the voids are filled with new bone tissue to
continuously provide adequate mechanical support to the
VB [19].
A radiopacifier is an essential component in VP and BKP
cements. However, addition of traditional radiopacifiers
significantly lowers the mechanical strength of ABCs. In
order to provide the ABC with adequate radiopacity yet
minimize mechanical property loss, new radiopacifiers have
been developed. For example, owing to the high
Table 1 Commercially available acrylic bone cements (ABCs).
Brand Prepolymer Monomer Radiopacifier Initiator and
additives
Working
time
(min)
Setting
time
(min)
Viscosity Bending
modulus
(MPa)
Bending
strength
(MPa)
Compressive
strength
(MPa)
Supplier
CMW1 PMMA: 88.85% MMA: 99.18% BaSO4: 9.1% BPO: 2.05%
DMPT: 0.82%
HQ: 0.0025%
6.5 11 High 2634 67.81 94.4 Depuy
CMW2 PMMA: 86.7% MMA: 99.18% BaSO4: 11.3% BPO: 2.0%
DMPT: 0.82%
HQ: 0.0025%
3 6 High 3008 74.3 97.8 Depuy
CMW3 PMMA: 88.0% MMA: 97.5% BaSO4: 10% BPO: 2.0%
DMPT: 2.50%
HQ: 0.0025%
5.5 11 Medium 2764 70.3 96.3 Depuy
Smartset HV PMMA-co-PMA: 84% MMA: 97.5% ZiO2: 15% BPO: 1%
DMPT: 2.5%
HQ: 0.0075%
8.0 12.5 High 3010 64.32 86.54 Depuy
Endurance PMMA: 67.5%
PMMA-co-PS: 21.1%
MMA: 98.0% BaSO4: 10% BPO: 1.85%
DMPT: 2.0%
HQ: 0.0011%
8.0 14 Low 2896 76.1 94 Depuy
Smartset MV PMMA-co-PS: 15e30%
PMMA: >50.0%
MMA: >50.0% BaSO4: 5e10% BPO: 1e3%
DMPT: 2.0%
8.0 14 Medium 3010 64.32 70 Depuy
Simplex P PMMA-co-PS: 73.5%
PMMA:15%
MMA: 97.45% BaSO4: 10% BPO: 1.5%
DMPT: 2.55%
HQ: 0.008%
7 14.3 Medium 2681 71 90.32 Stryker
Spineplex PMMA: 8.51%
PMMA-co-PS: 58.3%
MMA: 97.5% BaSO4: 30% BPO: 1.5%
DMPT: 2.5%
HQ: 0.0079%
10e12 8.7 Low 55.1 80.91 Stryker
Palacos R PMA: 83.9% MMA: 97.98% ZiO2: 15.3% BPO: 0.8%
DMPT: 2.0%
5.0 12.5 High 2628 72.2 79.6 Heraeus
Osteopal V PMMA-co-PMA: 54.6% MMA: 97.87% ZiO2: 45% BPO: 0.38%
DMPT: 2.13%
HQ
8 14 Low 3504  235 46  8 82  3 Heraeus
Cobalt HV PMMA-co-PMA:
83.55e84.65%
MMA: 98% ZiO2: 14.9% BPO: 0.5e1.6%
DMPT: 4.27%
5 10 High 67.84 96.04 Biomet
Osteobond PMMA-co-PS: 88.75% MMA: 99.26% BaSO4: 10% BPO:1.25%
DMPT: 0.745%
HQ: 0.008%
5 14.5 Low 2828 73.7 104.6 Zimmer
KyphX HV-R PMMA-co-PS: 68% MMA: 99.11% BaSO4: 30% BPO: 2%
DMPT: 0.888%
HQ: 0.0075%
8 20 High 111 Kyphon
ABC PMMA-co-PS: 99.55% MMA: 99% BPO: 4.5%
DMPT: 1%
HQ: 0.006%
4.5e6.5 12 Medium 3300 68 93 Tianjin Institute
of Synthetic
Materials Industry
BaSO4 Z barium sulphate; BPO Z benzoyl peroxide; DMPT Z NeN-dimethyl-p-toluidine; HQ Z hydroquinone; HV Z high viscosity; MMA Z methyl methacrylate; MPa Z megapascals;
MV Z medium viscosity; PMA Z poly(methyl acrylate); PMMA-co-PMA Z methyl methacrylate-methylacrylate copolymer; PMMA-co-PS Z methyl methacrylate-styrene copolymer;
ZiO2 Z zirconium dioxide.
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Bone cements for VP and BKP 5radiopacity of organobismuth, ABCs containing bismuth
salicylate showed higher radiopacity and better injection
properties compared to current commercial bone cements
while retaining good mechanical properties [15]. Surface
functionalization of existing radiopacifiers also appeared to
effectively improve the mechanical properties of cements
[20,21].
CPCs
A category of biodegradable bone cements, CPCs, were first
invented by Brown and Chow in the early 1980s [22].
Compared to ABCs, CPCs hold a unique combination of
osteoconductivity, injectability, mouldability, biodegrad-
ability, nonexothermic setting, and negligible shrinkage.
CPCs upon mixing form a viscous paste that can be easily
manipulated and moulded. Importantly, they can be
injected into the defect area and harden in vivo without
generating heat [23]. Therefore, CPCs are potentially an
ideal filling material for VP and BKP applications.
In general, all CPCs consist of a powder phase containing
one or more calcium phosphate (CaP) compounds (Table 2)
and a liquid phase, which can be water or a calcium- or
phosphate-containing aqueous solution. Despite the large
number of CaP combinations in different CPC systems
(Table 3), the setting chemistry is similarddissolution and
reprecipitation [22]. Based on the nature of the end hy-
dration product, which depends on the pH of the cement
paste, CPCs can be divided into two categories: apatite
(hydroxyapatite, HA; or calcium-deficient hydroxyapatite,
CDHA) (formed at pH > 4.2) and brushite (dicalcium phos-
phate dehydrate, DCPD) (formed at pH < 4.2) [24]. At a
physiological pH, brushite is one to two orders of magnitude
more soluble than apatite and degrades faster [25]. Due to
the short setting time, low mechanical strength, and infe-
rior injectability, brushite cements only have limited clin-
ical applications [26].
Biocompatibility and degradability of CPCs
Since CPCs consist of a network of CaP crystals that
resemble the HA in native bone tissue, they are considered
biocompatible and osteoconductive. In vivo, CPCs may
undergo passive and/or active absorption. The passiveTable 2 Calcium orthophosphates commonly used in bone cem
Compound name Abbreviation
Amorphous calcium phosphate ACP
Calcium-deficient hydroxyapatite CDHA
Dicalcium phosphate anhydrous DCPA
Dicalcium phosphate dihydrate DCPD
Hydroxyapatite HA
Monocalcium phosphate anhydrous MCPA
Monocalcium phosphate monohydrate MCPM
Octacalcium phosphate OCP
Tetracalcium phosphate TTCP
a-Tricalcium phosphate a-TCP
b-Tricalcium phosphate b-TCPabsorption relies mainly on solubility and dispersion of the
materials. The active resorption is related to the activity of
osteoclasts. Bone formation is initiated as soon as the
active and/or passive resorption of CPCs starts. Woven
bone usually forms after approximately 2 weeks. Depending
on the specific characteristics of CPCs, the implanted site
may be almost completely converted to bone within a few
months to a couple of years [27]. In addition, CPCs may
have bone-like elastic modulus, which helps prevent stress
shielding and maintain adequate toughness to prevent fa-
tigue fracture under cyclic loading [28].
Intrinsically, CPCs have nano/micron-sized pores. Their
porosity is approximately 30e50% [29]. While porosity can
be a limitation for them to be used in high load-bearing
sites, such a porous structure enables fluid exchange and
inclusion of growth factors, matrix proteins, and cells [30].
The micropores also significantly contribute to the resorp-
tion of CPCs and replacement of them by newly formed
bone. Owing to their inherent porosity, CPCs have been
widely used as carriers for controlled drug delivery [29,31].
Being able to function as both a supporting material and a
delivery system to release bioactive substances, CPCs have
been considered a promising cement material for bone
defect repair and vertebral augmentation.
Reinforcement of CPCs
From a clinical point of view, the mechanical strength of a
cement material should be similar to or greater than
cancellous bone. Although CPCs are highly promising for
bone regeneration, the usually poor mechanical properties
constitute a major challenge toward their applications. To
date, CPCs are mainly used at non- or moderate load-
bearing sites [22]. Therefore, mechanical reinforcement
has been a major challenge in CPC development. In addi-
tion to chemical composition (Table 3), the mechanical
properties of CPCs are markedly affected by granularity,
crystal type, powder/liquid ratio, and porosity.
Since CPCs are porous, decreasing the porosity by com-
pacting the cement paste prior to hydration has an imme-
diate boosting effect on their mechanical properties, while
increasing pore density and size causes mechanical strength
loss [32]. However, when CPC is compacted enough and its
porosity reaches a critical level (< 30%), its strength be-
comes constant [33]. It should be noted that whileents [64,74].
Chemical formula Ca/P ratio
Ca3(PO4)2$nH2O 1.2e2.2
Ca10x(HPO4)x(PO4)6ex(OH)2ex (0 <  < 1) 1.5e1.67
CaHPO4 1.00
CaHPO4$2H2O 1.00
Ca10(PO4)6(OH)2 1.67
Ca(H2PO4)2 0.50
Ca(H2PO4)2$H2O 0.50
Ca8H2(PO4)6 1.33
Ca4(PO4)2O 2.00
a-Ca3(PO4)2 1.50
b-Ca3(PO4)2 1.50
Table 3 Commercially available calcium phosphate cements (CPCs).
Brand Powder composition Initial
setting
time
Full
hardening
time
End product Porosity Pore size
(mm)
Degradability Injectability Compressive
strength
(MPa)
Supplier
BoneSource 72.3% TTCP, 27.7% DCPA 7 min 4 h Apatite 5e10% 33.4  6.2 Minimal No 26 Stryker
Norian SRS a-TCP, CaCO3, MCPM 10e15 min 12 h Carbonated
apatite
50% 47.2  21.9 Yes Yes 50 Synthes
a-BSM ACP, DCPD 15e20 min 1 h Apatite 80% <1 Yes Yes 4 ETEX
Biopex 75% a-TCP, 18% TTCP,
5% DCPD, 2% HA
7e10 min 24 h Apatite 40e50% Yes Yes 80 Mitsubishi
Calcibon a-TCP, DCPA, CaCO3, HA 10 min 6 h Carbonated
apatite
30e40% 41.6  22.0 Yes Yes 60 Biomet-Merck
Cementek a-TCP, TTCP, Ca(OH)2 3e15 min 24e48 h Apatite 50% 26 Yes Yes 13 Teknimed
Graftys HBS HA, TCP 15 min 72 h Apatite 65e70% 100e300 Yes Yes 12 Graftys
Graftys Quickset HA, TCP 8 min 24 h Apatite 70% 10e100 Yes Yes 24 Graftys
Ostim HA 20 min Apatite 53% 70 Yes Yes 0.24 Hereaus
chronOS Inject b-TCP, DCPD 6e12 min 24 h Brushite 60e75% 70e170 Yes Yes 3 Synthes
Embarc ACP, DCPD Apatite Yes Lorenz Surgical
Fracture Grout a-TCP, CaCO3 Apatite Yes Norian
Eurobone TCP, DCPD 3e15 min Apatite 2% 162.2  107.1 Yes 17 FH Orthopedics
KyphOs FS 5 min 24 h Apatite Yes 61 Kyphon
ACP Z amorphous calcium phosphate; DCPD Z dicalcium phosphate dihydrate; HA Z hydroxyapatite; MCPM Z monocalcium phosphate monohydrate; TCP Z tricalcium phosphate;
TTCP Z tetracalcium phosphate.
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Bone cements for VP and BKP 7pressurization improves the mechanical strength of CPCs, it
also deteriorates their injectability, making it difficult for
them to be used in MIS procedures [22].
Supplementation of certain compounds, including small
organic molecules, biodegradable polymers, proteins,
polysaccharides, inorganic molecules, bioceramics, and
bioglass, has proven effective in improving the mechanical
properties of CPCs. For example, adding citric acid into an
apatite cement paste increased both the injectability and
strength of the cement. This is likely because the citrate
ions facilitated the sliding and dispersion of apatite crys-
tals, inducing their growth and entanglement to form a
stronger matrix [34]. When CPC was blended with a
silanised-hydroxypropyl methylcellulose (Si-HPMC) hydro-
gel, the mechanical and handling properties were
improved, yet the rheological property was not affected
[35]. Recently, we found that supplementing silk fibroin
(SF) to CPCs helped improve their mechanical strength and
washout resistance [36]. Further, when a mineralized
complex, HAeSF, was supplemented to the CPC/SF com-
posite, the compressive strength of the composite
increased in a HAeSF content-dependent fashion, likely
due to the improved interfacial integrity and the presence
of nucleation seeds, which induced oriented growth of HA
crystals [37].
Inclusion of fibres, either nondegradable or biodegrad-
able, into CPCs can also improve their mechanical strength,
probably through a crack-arresting mechanism [22,38].
Depending on the strength, length, volume fraction, and
orientation of fibres, and fibreematrix interfacial adhesion,
the mechanical properties of fibre-reinforced CPCs (frCPCs)
may be up to two orders of magnitude higher than CPCs,
which permits their potential in load-bearing applications
[24,38]. Commonly used nondegradable fibres include
polyamides, carbon fibres, and glass fibres. Biodegradable
fibres include natural biomolecules such as proteins (e.g.,
collagen) and polysaccharides (e.g., chitosan) or synthetic
polymers such as poly(glycolic acid) (PGA), polylactide
(PLA), poly(lactic-co-glycolic acid) (PLGA), and poly-
caprolactone (PCL). In addition to the relatively long fibres,
whiskers made of HA, calcium carbonate, silicon nitride,
silicon carbide, or bioglass have also been used for
improving the mechanical strength of CPCs [39,40].CPCs for VP and BKP
While no commercially available CPC products have been
approved specifically for VP and BKP purposes, there have
indeed been many off-label uses of CPCs (Table 3) for
vertebral augmentation and spinal fusion. According to
biomechanical tests of vertebra filled with CPCs or PMMA by
VP/KP procedures, CPCs could restore the strength but not
stiffness of vertebra [41]. In the treatment of fractured
vertebra, both PMMA and CPCs restored strength and
stiffness and resulted in similar anterior vertebral height
restoration [42].
Using a canine VP model, Turner et al [43] compared the
histological responses and mechanical characteristics of
VBs injected with CPC (BoneSource, Stryker) or PMMA.
Histologically, both cement materials were well integrated
to VB bone tissue. Unlike PMMA, CPC underwent resorptionand remodelling with vascular invasion and bone ingrowth,
indicating its excellent biocompatibility and osteo-
conductivity. There was no significant difference in VB
height and compressive strength between PMMA- and CPC-
treated VBs. Interestingly, the compressive strength of
CPC-treated VBs continuously increased, whereas PMMA-
treated VBs presented decreased compressive strength,
indicating that CPC injection might have both intermediate
and short-term effects in treating vertebral defects.
The inconsistency of degradability of CPCs, possibly due
to the complexity in their composition, setting chemistry,
and environment, may present a major limitation toward
their clinical usage. For example, it has been reported that
no resorption of BoneSource was observed after several
years of implantation [44]. However, Turner et al [43] found
that BoneSource indeed degraded in a canine VP model.
Another study reported that approximately 30% of Bone-
Source was resorbed and replaced with bone after only 12
weeks, and 90% degraded after 40 weeks [45].Strontium-substituted CPCs
Strontium belongs to the same family as calcium in the
Periodic Table of Elements. Systematic administration of
strontium ranelate has been used to prevent bone loss and
stimulate bone regeneration [46]. Taking advantage of the
dual functions of strontium, strontium-modified CPC sys-
tems (Sr-CPCs) have recently been explored in order to
develop novel bioactive bone cements [47e51]. Different
ways to introduce strontium into the CPC paste, however,
may result in very different end products. When amorphous
Sr-substituted CaP and DCPD were mixed half and half,
strontium could be doped into the lattice of the HA, which
increased the lattice dimension and volume. However,
when a mixture of amorphous CaP and amorphous stron-
tium phosphate (SrP) were blended with DCPD, the HA and
Sr-hydroxyapatite (Sr-HA) precipitated separately in the
hydrated cement [52]. Therefore, in the majority of
studies, Sr-containing CaP was first synthesized and then
supplemented to the CPCs.
The supplementation of strontium to CPCs causes the
release of biologically effective doses of Sr2þ, which stim-
ulates bone formation in and around the implant and en-
hances osseointegration. In a critical-size metaphyseal
defect in the femur of ovariectomised rats filled with Sr-
CPC and CPC, a significant increase in bone formation was
achieved in the Sr-CPC group compared to the CPC group
[48]. However, the release of strontium from the Sr-CPC
implants did not lead to a serum Sr2þ level that was suffi-
ciently high to induce systemic bone mass increase [49].
In addition to promoting bone formation, Sr-CPCs also
show improved mechanical properties. Compared to non-
substituted CPCs, the compressive strength of Sr-CPCs can
achieve a high of 74.9 MPa [50,53] and may be further
improved upon surface treatment of the Sr compounds.
When the Sr-HA powder was surface-treated using acryl-
olpamidronate, the compression strength and stiffness of
the Sr-HA cement were improved by 22% and 14%, respec-
tively [54].
Furthermore, Sr-CPCs are radiopaque cements. The
radiopacity of brushite cements containing 10 wt%
8 Z. He et al.strontium halides was similar to or higher than that of
commercial radiopaque cements, which usually contain
20 wt% or more radiopacifiers [55]. With moderate me-
chanical strength yet without the need for the addition of
another radiopacifier, Sr-CPCs may be good candidates for
repairing nonloading sites or reinforcing osteoporotic
vertebrae through MISs [51].
Other types of bone cements
Besides ABCs and CPCs, there are also some other types of
bone cements. Taking advantage of the controllable
degradation, rapid solidification, excellent biocompati-
bility, and osteoconductivity of calcium sulfate (CaS), cal-
cium sulfate cements (CSCs) have been developed [28].
Compared to CPCs, CSCs have relatively higher mechanical
strength. However, CSCs not only cure very fast, but also
degrade fast. They may be fully absorbed within 6 weeks
upon implantation in vivo. Such fast degradation of the
filling material does not match the bone formation process.
Therefore, the development and clinical applications of
CSCs are relatively limited compared to CPCs [56].
Magnesium phosphate cement (MPC) is another type of
biodegradable bone cement. Because the released mag-
nesium ions can enhance the activity of osteoblasts, MPC
may function as a bioactive bone cement. However, the
setting time of MPCs is as short as 3 minutes, which largely
limits their applications. Similar to CSCs, MPCs are often
used in combination with other cement systems such as
CaPs and CaSs. Yang et al [57] mixed CaS powder with
magnesium phosphate (MgP) to form a CaP/MgP bone
cement. The setting time could be controlled up to 6 mi-
nutes by adjusting the content of MgP in the composite
cement. The compressive strength was up to 70 MPa.
Future development of VP/BKP cements
Ideally, the next generation of cements for VP and BKP
should have (a) adequate injectability, setting property,
cohesion, and radiopacity for best handling property; (b)
sufficient mechanical strength for immediate reinforce-
ment; (c) adequate porosity to allow body fluid circulation,
cell migration, and new bone ingrowth; (d) excellent
osteoconductivity and osteoinductivity for promoting new
bone formation; (e) moderate biodegradability so that the
resorption of cement material matches new bone forma-
tion; and (f) high efficiency of drug delivery [28]. In addi-
tion, future development of VB/BKP cements should also
take into consideration the following issues.
Mechanical characteristics
Bone cement is subjected to high stress and a challenging
body environment. As such, improving mechanical proper-
ties has been one of the main topics of bone cement
development. It should be noted, however, that higher
compressive strength of bone cements does not necessarily
mean a better choice. When a complex 3D load is applied
in vivo, the shear and tensile stresses, in addition to
compressive stress, indeed play a prominent role [58]. Thechoice of cement for augmentation of a fractured VB should
be based on comprehensive biomechanical considerations
including fracture configuration, rotational/flexional frac-
ture stability, load-bearing capacity, and the bone mineral
density of the VB [59].
The stiffness of VP/BKP cements should also be seriously
evaluated. Vertebrae augmentation using rigid ABCs (stiff-
ness being as high as 11 times that of osteoporotic vertebral
cancellous bone) may cause massive vertebrae stiffness
change [60]. Osteoporotic cancellous bone augmented by
rigid bone cement can be at least 12 times stiffer and 35
times stronger than untreated bone [61]. The rigid cement
augmentation leads to load increase in the structures
adjacent to the augmented VB, which may inhibit the
normal endplate to bulge into the augmented VB and thus
pressurizes adjacent discs, leading to increased loading of
untreated vertebra and even VB fracture. In addition, finite
element analyses showed that the compressive stiffness of
the spinal unit increased over 10% after VP using ABCs, yet
the hydrostatic pressure within the nucleus pulposus
increased by about 15% [62]. The stiffening effect of reg-
ular cement, however, can be largely avoided by using low-
modulus cements, which cause less stiffness alteration of
vertebrae and therefore better preservation of vertebrae
strength [60].Incorporation of bioactive additives and cells
Bone cements usually lack sufficient osteoinductivity.
Therefore, various bioactive, osteogenic agents are sup-
plemented in order to promote osteogenic differentiation
of progenitor cells and new bone formation. The incorpo-
ration of several bioactive ions, for example, strontium,
magnesium, zinc, copper, and fluoride, has been shown to
improve the biological performance of CPCs by promoting
bone metabolism [63].
Because of their intrinsic porosity and high surface area,
CPCs are an ideal carrier system for growth factor (GF) and
drug delivery. GFs such as bone morphogenetic proteins
(BMPs), basic fibroblast growth factor (bFGF), and vascular
endothelial growth factor (VEGF) have been incorporated
into CPCs, which improved their osteogenic and angiogenic
capabilities [64]. The GFs may be mixed with CPC compo-
nents alone, or be encapsulated within microspheres of
chitosan, gelatin, or hyaluronic acid before incorporation
into the CPC for best preservation of their bioactivity [65].
Plasmids or small interfering RNAs (siRNAs) may also be
incorporated into CPCs to achieve gene delivery to cells at
the injection area [64,66]. Recently, platelet-rich plasma
(PRP) and autologous bone marrow concentrate (BMC) have
been used together with CPCs as autologous bone sub-
stitutes [67].
In general, the bone metabolism of VP/BKP patients is
impaired due to the significantly reduced number and
functionality of osteogenic stem/progenitor cells. Delivery
of mesenchymal stem cells (MSCs) along with injection of
biodegradable bone cements such as CPCs, therefore, is
desirable for regenerating fractured VBs [68]. Since the
potential chemical or heat release during the cement
setting reaction may harm the cells, appropriate short-term
protection of cells is needed during cement handling.
Bone cements for VP and BKP 9Various biodegradable carriers including chitosan, alginate,
and fibrin have been used as encapsulating gels to protect
the cells [69]. With such protection, the cells remained in
the CPC with a high survival rate (close to 90%) and showed
excellent proliferation, osteo-differentiation, and miner-
alization upon implantation [70].
Radiopacifiers
The addition of traditional radiopacifiers to VP/BKP ce-
ments may affect cement setting behaviour and signifi-
cantly reduce the mechanical strength of cements. It may
even significantly increase bone resorption, likely as a
result of enhanced macrophage/osteoclast differentiation
[71]. In the development of new radiopacifiers, the surface
functionalization of existing radiopacifiers appears to be an
effective way to overcome such problems. Using barium
sulfate or zirconia dioxide nanoparticles that were surface-
treated with a difunctional agent, usually an acrylated
compound which can be copolymerized with MMA, the
interface between radiopacifier particles and PMMA was
ameliorated, resulting in enhanced mechanical properties
of ABCs [20,21]. Supplementing MMA-treated, Sr-HA to ABCs
not only improved the handling property and compressive
strength of ABCs, but also enhanced their radiopacity and
bioactivity [72].
Hybrid cements
Currently, various PMMA-based hybrid or composite ce-
ments have been developed by incorporating CaPs or
polymers in order to combine the bone augmentation
characteristics of ABCs and biodegradability of CPCs. Such
studies may eventually lead to the development of a range
of bone cements that are tailored for specific VP or BKP
needs. For example, for young patients with traumatic
burst fractures, excellent biocompatibility and degrad-
ability of cement are required to facilitate bone formation
and remodelling. In elderly OVCF patients, however, im-
mediate weight-bearing stability is more important.
Therefore, cements that provide long-term multidirec-
tional stability and are slowly resorbed are needed. For
application in metastatic lesions or osteoid osteomata, the
cement could be designed to produce local heat and resolve
quickly. Developing cements with characteristics matching
the needs of specific VP/BKP indications, therefore, may
help solve many practical issues and lead to better treat-
ment outcomes yet reduced complications [59].
Concluding remarks
To date, a broad range of bone cements have been
approved for clinical applications and many have been used
for VP and BKP procedures. While ABCs still prevail as the
VP/BKP filling material of choice, their intrinsic non-
degradability constitutes a formidable obstacle toward
broader applications. By contrast, given the unique com-
bination of biodegradability, osteoconductivity, mould-
ability, nonexothermic setting, and negligible shrinkage,
CPCs are determined to play a significant role in the
development of next-generation VP/BKP cements. Beingable to simultaneously promote bone formation yet sup-
press bone resorption, Sr-CPCs represent a promising type
of bone cement for augmentation of fractured vertebra.
New technical advances in the development of VP/BKP
cements rely on innovative concepts and interdisciplinary
knowledge. With the advent of new biodegradable and
mechanically matched bone cements, the indications of
VP/BKP will likely be broadened, for example, to VCFs with
no neurological symptoms in the elderly or even traumatic
VCFs in young adults. These types of fractures require bone
cements with adjustable mechanical properties that meet
the loading requirements early and can be absorbed to
avoid stress shielding in the later stage of treatment. If
achieved, patients suffering from such fractures may no
longer need extra vertebral fixation surgeries. Therefore, a
wide spectrum of spinal lesions that were previously left
untreated may potentially benefit from these ongoing ad-
vancements of bone cements.Conflicts of interest
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